Ascidian Therapeutics Strengthens Leadership with New CDO and Advisory Board for Stargardt Disease Treatment Ascidian Therapeutics appoints Dr. Murray A. Abramson as CDO and forms an advisory board aimed at advancing ACDN-01 for Stargardt disease.

Ascidian Therapeutics Strengthens Leadership with New CDO and Advisory Board for Stargardt Disease Treatment #United_States #Boston #Stargardt_Disease #Ascidian_Therapeutics #Dr._Murray_A._Abramson

SpliceBio Raises $135 Million in Series B to Propel Genetic Medicine Innovations Against Stargardt Disease SpliceBio has secured $135 million in Series B financing to develop SB-007 for Stargardt disease and expand its pipeline of genetic therapies, enhancing treatments for complex genetic conditions.

SpliceBio Raises $135 Million in Series B to Propel Genetic Medicine Innovations Against Stargardt Disease #Spain #Barcelona #SpliceBio #SB-007 #Stargardt_Disease

SpliceBio Secures FDA Approval for Innovative Stargardt Disease Treatment SB-007 SpliceBio's SB-007 has received FDA IND clearance, marking a breakthrough in treating Stargardt disease. This therapy targets the root cause of the condition across all mutations.

SpliceBio Secures FDA Approval for Innovative Stargardt Disease Treatment SB-007 #Spain #Barcelona #SpliceBio #SB-007 #Stargardt_Disease